Paragon Biosciences has developed the first AI-based diagnostic tool to be approved for use in radiology by the US FDA. The system, called QuantX, was designed in collaboration with Qlarity Imaging and is used to help radiologists assess MRIs looking for breast cancer. “AI can now provide a more accurate diagnosis of cancer than any human being can,” said Dr. David L. Cohen, CEO of Paragon BioSciences.
Paragon Biosciences has developed the first AI-based diagnostic tool to be approved for use in radiology by the US FDA. The system, called QuantX, was designed in collaboration with Qlarity Imaging and is used to help radiologists assess MRIs looking for breast cancer. In a clinical study, the tool reduced missed breast cancers by 39%, while improving overall diagnostic performance by 20%.